Revolution Medicines, Inc.

For the period ended Dec 31, 2025. Filed Feb 25, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Feb 25, 2026

RVMD$193.06-3.5%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Stockholders’ Equity

(in thousands, except share and share data)

Accumulated
Additional · Other · Total
Common Stock · Paid-in · Comprehensive · Accumulated · Stockholders'
	Shares	Amount	Capital	Income/ (Loss)	Deficit	Equity
Balance at December 31, 2022	90,411,912	$9	$1,388,300	$(1,780)	$(701,341)	$685,188
Issuance of common stock pursuant to stock option exercises	524,094	—	3,316	—	—	3,316
Issuance of common stock from follow-on public offering, net of offering costs of $21,294	15,681,818	2	323,704	—	—	323,706
Issuance of common stock in connection with acquisition of EQRx, Inc., net of transaction costs of $20,717	54,786,528	5	1,120,880	—	—	1,120,885
Issuance of common stock from at-the-market offering	2,482,880	—	62,053	—	—	62,053
Issuance of common stock related to vesting of restricted stock units	576,974	—	—	—	—	—
Issuance of common stock related to employee stock purchase plan	210,679	—	3,317	—	—	3,317
Repurchases of early exercised stock	(291)	—	—	—	—	—
Stock-based compensation expense	—	—	61,772	—	—	61,772
Net unrealized gain on marketable securities	—	—	—	2,324	—	2,324
Net loss	—	—	—	—	(436,367)	(436,367)
Balance at December 31, 2023	164,674,594	$16	$2,963,342	$544	$(1,137,708)	$1,826,194
Issuance of common stock pursuant to stock option exercises	927,275	—	12,330	—	—	12,330
Issuance of common stock from follow-on public offering, net of offering costs of $34,881	16,576,088	2	727,618	—	—	727,620
Issuance of pre-funded warrants, net of issuance costs of $4,578	—	—	95,422	—	—	95,422
Issuance of common stock from at-the-market offering	2,441,943	—	118,728	—	—	118,728
Issuance of common stock related to vesting of restricted stock units	1,011,255	—	—	—	—	—
Issuance of common stock related to employee stock purchase plan	265,470	—	5,029	—	—	5,029
Stock-based compensation expense	—	—	79,197	—	—	79,197
Net unrealized gain on marketable securities	—	—	—	777	—	777
Net loss	—	—	—	—	(600,093)	(600,093)
Balance at December 31, 2024	185,896,625	$18	$4,001,666	$1,321	$(1,737,801)	$2,265,204
Issuance of common stock pursuant to stock option exercises	1,147,005	—	21,134	—	—	21,134
Issuance of common stock pursuant to exercise of prefunded warrants	2,173,911	—	—	—	—	—
Issuance of common stock from at-the-market offering	6,163,501	1	347,914	—	—	347,915
Issuance of common stock related to vesting of restricted stock units	1,349,291	—	—	—	—	—
Issuance of common stock related to employee stock purchase plan	271,045	—	8,036	—	—	8,036
Exercise of warrants	23	—	4	—	—	4
Stock-based compensation expense	—	—	118,389	—	—	118,389
Net unrealized gain on marketable securities	—	—	—	1,916	—	1,916
Net loss	—	—	—	—	(1,131,301)	(1,131,301)
Balance at December 31, 2025	197,001,401	$19	$4,497,143	$3,237	$(2,869,102)	$1,631,297

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.